4 medicines are fake and 49 are of low quality, CDSCO report exposes the 'dirty game' of pharmaceutical companies
The Central Drugs Standard Control Organization (CDSCO) has recently issued a warning in which some batches of medicines have been found to be fake and not up to the standard quality.
The Central Drugs Standard Control Organization (CDSCO) has recently issued a warning in which some batches of medicines have been found to be fake and not up to standard quality. In its monthly inspection, CDSCO has declared four medicines as fake and has put 49 medicines and formulations in the 'quality deficient' list. CDSCO found that out of 3 thousand medicines, 49 medicines have failed the quality test. These medicines are now being recalled on the basis of batch.
According to CDSCO, these monthly inspections have brought down the percentage of substandard medicines in India to just 1 per cent. Drugs Controller General of India (DCGI) Dr Rajiv Singh Raghuvanshi said that only 1.5 per cent of the total medicines were found to be sub-standard. These include some important drugs such as Metronidazole tablets from Hindustan Antibiotics, Domperidone tablets from Rainbow Life Sciences, Oxytocin from Pushkar Pharma, Metformin from Swiss Biotech Parenterals, Calcium and Vitamin D3 tablets from Life Max Cancer Laboratories and PAN 40 from Alkem Labs.
Specifically, paracetamol tablets manufactured by Karnataka Antibiotics and Pharmaceuticals Ltd have been listed due to quality concerns. The report also includes calcium and vitamin D3 supplements, anti-diabetes pills and high blood pressure medicines. A non-sterile gauze roller bandage has also been placed in the NSQ category.
What are NSQ medicines?
Low quality (NSQ) medicines are those that do not comply with national or international quality standards. Such medicines can be harmful to the health of patients and their effect is also less than expected. CDSCO's monthly inspection has once again highlighted how important it is to ensure the circulation of quality medicines in India.
Last month, more than 50 medicines failed the quality test.
Last month too, CDSCO had declared more than 50 medicines as having failed the quality test. This cautious approach of CDSCO is aimed at reducing the percentage of fake and low-quality medicines in the Indian market, so that the safety of patients can be ensured.